0.14USD
−14.927MUSD
47.638MUSD
64.71M
About Protalix BioTherapeutics, Inc. (DE)
Sector
CEO
Dror Bashan
Headquarters
Carmiel
Website
Employees (FY)
197
Founded
1993
ISIN
US74365A3095
Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Carmiel, Israel.
mid term +15,000%Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company o
$PLX - Inv SHS opportunity (EC tomorrow, BLA approval Apr27)Trigger above 5.5 (To the next resistance 5.8).
Very risky as well as catalysts opportunity movement.
Not recommended to buy or Sell PLX stocks!
Ready For A PopSteady accumulation over the last few weeks - looking ready to run with fundamentals catalysts of PDUFA and final Phase 3 data readout for PRX-102 in April
PLX Releases Phase 3 Trial Data tomorrow at 1:24 pm ESTPlease don't miss out on this one. If you are already a follower of me, you know that phase 3 trial data means very good things. Take a look at my idea on GMDA. like and follow for more picks like this!
$PLX - "Buy on rumor sell on news"?, Yet, BLA and BRIGHT aheadProtalix presented a good results yesterday on top line results with BRIDGE (Switch over from Refagal),
Link is below:
protalixbiotherapeutics.gcs-web.com
At this point, the main support is 5.29$ (Golden Pocket support)
Gap open below at 4.91
With expectation to the reversal .
Not recommended
$PLX - One of my faves, Creating Positive MomentumPLX Could Claim Substantial Global Market Share In Fabry Disease.
April 27, BLA approval opportunity.
Technically, resistances in rage, 4.87 and 5.2.
Support level 4.4-4.35.
Not recommended to buy or sell PLX stocks (Very risky).
Just an Idea.
$PLX - The most important year for PROTALIX Final FDA decision for BLA approval will take place on April 27.
In terms of technical aspects:
Bullish flag opportunity on sight, trigger for long with breaking above 4.74.
Main support 4.35-4.4
Not recommended to buy or sell PLX stocks.
Very risky stock and stage,
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
